Biotech & Pharma

Circio and GenAssist Collaborate on Gene Therapy for Muscle Disease and In Vivo Cell Therapy

28 sec read7 views0 listens

Circio and GenAssist are collaborating to develop next-generation gene therapy candidates by integrating circular RNA technology with tissue-specific AAV vectors. This technical synergy allows developers to overcome the traditional dose-expression trade-off, enabling effective muscle-specific treatment at significantly lower doses while eliminating off-target toxicity. The partnership is now focused on validating these enhanced expression cassettes for broader applications in oncology and autoimmune in vivo cell therapies.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Pharma's Trial Problem: Outdated Systems, Broken Data, and the Coming AI Reset

Clinical trials in biopharmaceutical R&D are increasingly resource-intensive due to outdated systems and poor data management, despite advancements in science. AI could revolutionize this process but is hindered by the lack of structured, clinica...

Ali Nemati

Biotech & Pharma1 day ago21 sec read

Targeted Protein Degradation Broadens Its Scope

Targeted protein degradation (TPD) technologies are advancing to tackle extracellular proteins, expanding their therapeutic potential beyond intracellular targets. This development is crucial for addressing diseases driven by membrane-bound or secret...

Ali Nemati

Biotech & Pharma1 day ago28 sec read

Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead

The FDA and NIH are pushing for a reduction in animal testing, promoting the use of organ-on-chip systems as validated new approach methodologies (NAMs). This shift is crucial for developers aiming to integrate these technologies into regulatory fram...

Ali Nemati

Biotech & Pharma1 day ago25 sec read

State of the Diagnostic Industry: Recombinants on the Rise

The clinical diagnostic industry is rapidly transitioning to recombinant proteins, overcoming initial skepticism due to supply chain vulnerabilities and ethical concerns. This shift ensures more reliable and sustainable sourcing for critical diagnost...

Ali Nemati

Health & Medicine1 day ago28 sec read

STAT+: Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more

Revolution Medicines presented positive clinical trial data for daraxonrasib, a pancreatic cancer treatment, showing a significant survival benefit over standard chemotherapy. This development highlights the potential of targeted therapies in oncolog...

Ali Nemati

Circio and GenAssist Collaborate on Gene Therapy for Muscle Disease and In Vivo Cell Therapy

Related Articles

Pharma's Trial Problem: Outdated Systems, Broken Data, and the Coming AI Reset

Targeted Protein Degradation Broadens Its Scope

Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead

State of the Diagnostic Industry: Recombinants on the Rise

STAT+: Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more